In a new study, the RSV drug nirsevimab was 93% effective at preventing young children from being hospitalized for the ...

This analysis documented the continued high burden of medically attended respiratory syncytial virus (RSV)-associated acute ...

This analysis documented the continued high burden of medically attended respiratory syncytial virus (RSV)-associated acute respiratory illness among young children in the U.S. Nirsevimab and maternal ...

New York City data highlight the benefits of early administration of nirsevimab to safeguard infants from respiratory ...

RSV cases, hospitalisations and ICU admissions notified in 12 weeks to mid-November were between six and seven times lower ...

RSV season is beginning, but for the first time, parents can access an effective treatment to protect their infants from this common but dangerous virus.

The first study, published yesterday in Clinical Infectious Diseases, includes results of a phase 3 clinical trial (MELODY), ...

Coughing, sneezing, wheezing? High fever and no sleep? Your child may have RSV.

Seasonal maternal respiratory syncytial virus (RSV) vaccination and nirsevimab for infants demonstrate cost-effectiveness.

Use of nirsevimab was associated with an approximately 80% reduction in illness due to respiratory syncytial virus (RSV) ...

A recently approved immunization drug is helping to limit the severity of a respiratory disease that afflicts young children ...

The following is a summary of “Parent Perspectives on Nirsevimab for Their Newborn,” published in the November 2024 issue of ...